Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.71 USD
Change Today +0.036 / 5.37%
Volume 284.6K
NBY On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

novabay pharmaceuticals inc (NBY) Snapshot

Open
$0.68
Previous Close
$0.67
Day High
$0.71
Day Low
$0.66
52 Week High
08/18/14 - $1.30
52 Week Low
02/27/15 - $0.42
Market Cap
43.1M
Average Volume 10 Days
580.9K
EPS TTM
$-0.31
Shares Outstanding
61.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVABAY PHARMACEUTICALS INC (NBY)

Related News

No related news articles were found.

novabay pharmaceuticals inc (NBY) Related Businessweek News

No Related Businessweek News Found

novabay pharmaceuticals inc (NBY) Details

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It offers Aganocide compounds, including auriclosene irrigation solution to reduce urinary catheter blockage and encrustation; an eye drop formulation of auriclosene for treating adenoviral conjunctivitis; and a gel formulation of auriclosene for treating impetigo, a highly contagious skin infection. The company also provides NeutroPhase, a skin and wound cleanser for non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

novabay pharmaceuticals inc (NBY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $478.5K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $318.8K
Senior Vice President of Product Development
Total Annual Compensation: $250.0K
Senior Vice President of Business & Corporate...
Total Annual Compensation: $281.3K
Compensation as of Fiscal Year 2014.

novabay pharmaceuticals inc (NBY) Key Developments

NovaBay Pharmaceuticals, Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

NovaBay Pharmaceuticals, Inc. reported consolidated financial results for the fourth quarter and year ended December 31, 2014. Net loss for the fourth quarter of 2014 was $4.5 million, or $0.09 per share, compared with a net loss for the fourth quarter of 2013 of $4.1 million, or $0.10 per share. The higher net loss in the 2014 quarter was due to spending on sales and marketing activities for Avenova, offset partially by lower spending on research and development. Operating loss was $4,901,000 against $4,867,000 for the same period of last year. Loss before provision for income taxes was $4,476,000 against $4,144,000 for the same period of last year. It reported sales revenue of $385,000 for the quarter ended December 31, 2014 against $144,000 a year ago. Net loss for 2014 was $15.2 million, or $0.31 per share, compared with a net loss for 2013 of $16.0 million, or $0.42 per share. The lower net loss in 2014 was due mainly to decreased spending on research and development activities in 2014, partially offset by collaboration revenue from Galderma recorded in 2013 and spending on sales and marketing activities for Avenova beginning in August 2014. NovaBay sales revenue for 2014 of $684,000 increased from $223,000 in 2013 primarily due to the introduction of Avenova in August. Operating loss was $16,878,000 against $15,486,000 for the same period of last year. Loss before provision for income taxes was $15,192,000 against $16,040,000 for the same period of last year.

NovaBay Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 26, 2015

NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2014 results After-Market on Mar 26, 2015

NovaBay Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 26, 2015

NovaBay Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBY:US $0.71 USD +0.036

NBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NBY.
View Industry Companies
 

Industry Analysis

NBY

Industry Average

Valuation NBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.7x
Price/Book 18.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVABAY PHARMACEUTICALS INC, please visit www.novabaypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.